ES2035668T3 - Uso de moleculas de adherencia intercelular y sus ligandos de union en el tratamiento del asma. - Google Patents

Uso de moleculas de adherencia intercelular y sus ligandos de union en el tratamiento del asma.

Info

Publication number
ES2035668T3
ES2035668T3 ES199090104423T ES90104423T ES2035668T3 ES 2035668 T3 ES2035668 T3 ES 2035668T3 ES 199090104423 T ES199090104423 T ES 199090104423T ES 90104423 T ES90104423 T ES 90104423T ES 2035668 T3 ES2035668 T3 ES 2035668T3
Authority
ES
Spain
Prior art keywords
asthma
treatment
molecules
intercellular
union links
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES199090104423T
Other languages
English (en)
Spanish (es)
Inventor
Craig D. Wegner
Robert H. Gundel
Robert Rothlein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2035668T3 publication Critical patent/ES2035668T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES199090104423T 1989-03-09 1990-03-08 Uso de moleculas de adherencia intercelular y sus ligandos de union en el tratamiento del asma. Expired - Lifetime ES2035668T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32123789A 1989-03-09 1989-03-09
US32123989A 1989-03-09 1989-03-09
US32101889A 1989-03-09 1989-03-09
US32448189A 1989-03-16 1989-03-16
US40140989A 1989-09-01 1989-09-01

Publications (1)

Publication Number Publication Date
ES2035668T3 true ES2035668T3 (es) 1993-04-16

Family

ID=27541038

Family Applications (1)

Application Number Title Priority Date Filing Date
ES199090104423T Expired - Lifetime ES2035668T3 (es) 1989-03-09 1990-03-08 Uso de moleculas de adherencia intercelular y sus ligandos de union en el tratamiento del asma.

Country Status (13)

Country Link
EP (1) EP0387701B1 (en:Method)
JP (1) JP3119483B2 (en:Method)
KR (1) KR0177519B1 (en:Method)
AT (1) ATE79270T1 (en:Method)
AU (1) AU638450B2 (en:Method)
CA (1) CA2047721C (en:Method)
DE (1) DE69000248T2 (en:Method)
DK (1) DK0387701T3 (en:Method)
ES (1) ES2035668T3 (en:Method)
GR (1) GR3006073T3 (en:Method)
HU (1) HU216313B (en:Method)
NZ (1) NZ232868A (en:Method)
WO (1) WO1990010453A1 (en:Method)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68929096T2 (de) 1988-09-01 2000-05-11 Bayer Corp., Pittsburgh Menschliches Rhinovirusrezeptorprotein, das die Virusinfektionsanfälligkeit hemmt
US6051231A (en) * 1988-09-01 2000-04-18 Bayer Corporation Antiviral methods and prepations
US6143298A (en) * 1988-09-01 2000-11-07 Bayer Corporation Soluble truncated forms of ICAM-1
ZA896668B (en) * 1988-09-01 1990-06-27 Molecular Therapeutics Inc A human rhinovirus receptor protein that inhibits virus infectivity
US6514936B1 (en) 1988-09-01 2003-02-04 Bayer Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)
US5776775A (en) * 1989-02-21 1998-07-07 Dana-Farber Cancer Institute Anti-LAM 1-3 antibody and hybridoma
ES2134762T3 (es) * 1990-07-20 1999-10-16 Bayer Ag Formas multimericas de proteinas receptoras de rinovirus humanos.
US5686581A (en) * 1990-07-20 1997-11-11 Bayer Corporation Multimeric form of human rhinovirus receptor protein
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
US5686582A (en) * 1990-07-20 1997-11-11 Bayer Corporation Multimeric forms of human rhinovirus receptor protein
CA2092801A1 (en) * 1990-10-03 1992-04-04 Randall Barton Method for treating inflammation using anti-idiotypic antibodies
CA2056143A1 (en) * 1990-11-28 1992-05-29 Michael S. Diamond The mac-1 binding site of icam-1
ES2094837T3 (es) * 1991-04-03 1997-02-01 Boehringer Ingelheim Pharma Metodo para inhibir la toxicidad pulmonar por oxigeno.
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
DK0551501T3 (da) * 1991-07-31 1999-08-02 Baylor College Medicine Anvendelse af endotheliel-leukocyt-adhæsions-
WO1993006864A1 (en) * 1991-10-01 1993-04-15 The General Hospital Corporation Preventing allograft rejection with antibodies to adhesion molecules
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5708141A (en) * 1992-05-11 1998-01-13 Corvas International, Inc. Neutrophil inhibitors
EP0604624A4 (en) * 1992-06-22 1997-03-12 Miles Inc MULTIMERE FORMS OF HUMAN RHINOVIRUS RECEPTOR PROTEIN.
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
EP1578917A4 (en) 2001-07-19 2008-01-23 Perlan Therapeutics Inc MULTIMEDIA PROTEINS AND METHODS FOR THE PRODUCTION AND USE THEREOF
GB0525214D0 (en) 2005-12-12 2006-01-18 Bioinvent Int Ab Biological materials and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3854536T2 (de) * 1987-05-04 1996-03-07 Dana Farber Cancer Inst Inc Interzellulare Adhäsions-Moleküle und deren Bindungsliganden.
DE3852374T2 (de) * 1987-11-02 1995-05-04 Baylor College Medicine Verwendung von ICAM-1 oder ihre funktionelle Derivate zur Behandlung unspezifischer Entzündungen.
CA1341055C (en) * 1987-12-08 2000-07-18 Alan Mcclelland Transfectant cell lines which express the major human rhinovirus receptor

Also Published As

Publication number Publication date
CA2047721C (en) 2004-01-06
KR920700667A (ko) 1992-08-10
JP3119483B2 (ja) 2000-12-18
HU902883D0 (en) 1991-12-30
HU216313B (hu) 1999-06-28
AU5349990A (en) 1990-10-09
JPH04504127A (ja) 1992-07-23
DE69000248D1 (de) 1992-09-17
GR3006073T3 (en:Method) 1993-06-21
HUT65843A (en) 1994-07-28
DK0387701T3 (da) 1992-12-07
WO1990010453A1 (en) 1990-09-20
DE69000248T2 (de) 1993-01-07
ATE79270T1 (de) 1992-08-15
NZ232868A (en) 1995-05-26
EP0387701A1 (en) 1990-09-19
CA2047721A1 (en) 1990-09-10
KR0177519B1 (ko) 1999-03-20
EP0387701B1 (en) 1992-08-12
AU638450B2 (en) 1993-07-01

Similar Documents

Publication Publication Date Title
ES2035668T3 (es) Uso de moleculas de adherencia intercelular y sus ligandos de union en el tratamiento del asma.
DE3852909D1 (de) Lineare Kette von Parallelprozessoren und Benutzungsverfahren davon.
ID23374A (id) Halogenopirimidin
DE69130445D1 (de) Die Mac-1-Bindungsstelle von ICAM-1
DK0745852T3 (da) Anvendelse af funktionelle derivater af intercellulær adhæsion-molekylet ICAM-1 i antiviral terapi
DE69813839D1 (de) Verwendung von n,n-bis (phenylcarbamoylmethyl) dimethylammoniumchlorid und derivaten davon zur behandlung von chronischem schmerz
DE3876688D1 (de) Thixothrope anstrichmittelzusammensetzung und gegenstaende damit.
ES2056180T3 (es) Nuevos derivados de 2'-halometiliden, 2'-eteniliden y 2'-etinil citidina.
ES2043609T3 (es) Composiciones de interleucina-2.
DE59004875D1 (de) Falzapparat zum Herstellen von längs- und/oder quergefalzten Produkten.
ATE147746T1 (de) Derivate von fluorphosphonat-nukleotiden
ES2181787T3 (es) Derivados de la 3h-2,3-benzodiazepina sustituidos en posicion 3, y su su utilizacion como medicamentos
ATE311399T1 (de) 2'-deoxy-4'-thioribonucleoside als antivirale und antikrebsmittel
ES2104917T3 (es) Bis-naftalimidas que contienen engarces amido y tioamido como agentes anticancerosos.
DE3576689D1 (de) Oxa- und thiadiazolylderivate und ihre verwendung.
ATE56873T1 (de) Verwendung von hygromycin und epihygromycin zur behandlung von dysentrie bei schweinen.
DE3767175D1 (de) Therapeutische zusammenstellungen auf basis von 3-alkoxyflavonen und derivate von 3-alkoxyflavonen.
ES2072869T3 (es) Uso de derivados de la 1,4-dihidropiridina en el tratamiento del alcoholismo.
ATE165594T1 (de) Triarylethylenderivate zur therapeutischen verwendung
ATE57526T1 (de) P-acylaminobenzamide.
ES2061775T3 (es) Derivados de estrobirulina, su obtencion y empleo.
GR1000955B (el) Μεθοδος παρασκευης παραγωγων φωσφορικης μιτομυκινης
DK74889D0 (da) Alkanoyl- og aroyloxazoloner
DE69421665D1 (de) Anomere Fluorribosylamine
ES2066897T3 (es) 5,11-dihidro-6h-pirido(2,3-b)(1,4)benzodiazepin-6-onas y -tionas y su uso en la prevencion o el tratamiento del sida.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 387701

Country of ref document: ES